Centessa Pharmaceuticals (NASDAQ:CNTA) PT Raised to $20.00 at BMO Capital Markets

Centessa Pharmaceuticals (NASDAQ:CNTA) had its price objective increased by investment analysts at BMO Capital Markets from $15.00 to $20.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. BMO Capital Markets’ target price indicates a potential upside of 37.17% from the stock’s current price.

A number of other research analysts have also commented on CNTA. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Morgan Stanley increased their target price on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Friday, June 21st.

Centessa Pharmaceuticals Trading Down 2.3 %

CNTA opened at $14.58 on Monday. The business has a 50 day simple moving average of $11.36 and a two-hundred day simple moving average of $10.39. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -10.27 and a beta of 1.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29. Centessa Pharmaceuticals has a one year low of $5.15 and a one year high of $17.25.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Analysts predict that Centessa Pharmaceuticals will post -1.61 EPS for the current year.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 12,198 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total transaction of $148,449.66. Following the completion of the transaction, the insider now owns 241,171 shares of the company’s stock, valued at approximately $2,935,051.07. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 25,000 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.00, for a total transaction of $375,000.00. Following the sale, the insider now directly owns 223,369 shares in the company, valued at approximately $3,350,535. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Gregory M. Weinhoff sold 12,198 shares of the stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total value of $148,449.66. Following the sale, the insider now owns 241,171 shares in the company, valued at $2,935,051.07. The disclosure for this sale can be found here. Insiders sold a total of 41,873 shares of company stock valued at $581,000 in the last 90 days. Corporate insiders own 11.59% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Quarry LP grew its holdings in shares of Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after acquiring an additional 3,108 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 69.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock worth $122,000 after acquiring an additional 4,423 shares during the period. EntryPoint Capital LLC bought a new stake in shares of Centessa Pharmaceuticals in the first quarter worth $109,000. Sandia Investment Management LP bought a new stake in shares of Centessa Pharmaceuticals in the second quarter worth $90,000. Finally, Fred Alger Management LLC bought a new stake in shares of Centessa Pharmaceuticals in the second quarter worth $99,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.